ORCID
Zheng Jiao: https://orcid.org/0000-0001-7999-7162
Yue-ting Chen: https://orcid.org/0000-0001-9911-2181
Chen-yu Wang: https://orcid.org/0000-0003-1808-361X
Yin-yi Wei: https://orcid.org/0000-0002-1914-7577
Zi-ran Li: https://orcid.org/0000-0001-6740-6003
Min Zhu: https://orcid.org/0000-0001-6963-1220
What is already known about this subject
Oxcarbazepine is commonly used as monotherapy or adjunctive therapy for partial seizures.In vivo , it rapidly transforms to 10-hydroxycarbazepine,an active metabolite that deliveries majority antiepileptic effect.
Due to the high pharmacokinetic variability of 10-hydroxycarbazepine, many population pharmacokinetic models have been developed to optimise the dosing regimen of oxcarbazepine. However, the published population pharmacokinetics information has not been reviewed.